Effect of metformin, acarbose and pioglitazone hydrochloride on incipient type 2 diabetes mellitus

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044110

Enrollment

Unknown

Registered

2021-03-11

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

experimental group:Metformin+Acarbose +Pioglitazone

control group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.The diagnosis of T2DM was in accordance with the World Health Organization (WHO) criteria of 1999; 2.Age from 18 to 75, male or famale.

Exclusion criteria

Exclusion criteria: 1.Pregnancy or possible pregnancy, cardiovascular disease (CVD); 2.Hepatic insufficiency (ALT orAST > 2*ULN); 3.Renal insufficiency [estimate glomerular filtration rate (eGFR) <60ml/min estimated from Modification of Diet in Renal Disease (MDRD) equation]; 4.Thyroid disease, infectious disease, cancer, and/or systemic inflammatory diseases.

Design outcomes

Primary

Measure	Time frame
VEGF;FGF21;adiponectin;Urinary microalbumin /creatinine ratio;INS;fasting blood-glucose;Glycosuria hemoglobin;	—

Countries

China

Contacts

Public ContactXiaomeng Sun

Beijing Chao-Yang Hospital, Capital Medical University

beijingxiaosun2010@163.com+86 18515310339

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026